Decoy Therapeutics Inc
DCOY Healthcare Biotechnology
In the quarter to June 2026, revenue fell 84.6%, EPS grew 94.5% and free cash flow fell 212.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow DCOY
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more TTM periods Free account |
(5.00) | (12.52) | (13.03) | (14.45) |
Depreciation & Amortization |
0.00 | 0.01 | 0.01 | 0.02 | |
Non Cash Items (Other) |
0.13 | 8.73 | 8.91 | 9.09 | |
Accounts Payable Change |
0.80 | (1.17) | (1.43) | (1.74) | |
Change in payables and accrued liability |
0.15 | (0.30) | (1.11) | (1.18) | |
Change in other assets and liabilities |
(0.52) | 0.42 | 0.11 | (0.07) | |
Operating Cash Flow |
(4.43) | (4.83) | (6.53) | (8.32) | |
Capital expenditures |
— | (0.57) | — | (0.62) | |
Net Aquisitions |
— | 1.55 | — | — | |
Investing cash flow |
(0.20) | 0.76 | — | 0.72 | |
Repayment/Issuance of Debt (Net) |
(0.33) | (0.22) | — | — | |
Equity Repurchase (Common, Net) |
6.49 | 12.56 | — | 15.07 | |
Financing cash flow |
6.16 | 12.34 | — | 14.96 | |
Change in Cash |
1.53 | 8.28 | 6.02 | 7.49 | |
Beginning Cash |
2.43 | 2.43 | 10.71 | 10.71 | |
Ending Cash |
3.96 | 10.71 | 16.73 | 18.20 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
0.44 | (1.05) | (2.42) | (2.99) | |
Issuance/Purchase of Shares |
6.49 | 12.56 | — | 15.07 |